The U.S. Department of Justice continued its health care fraud winning streak as it reached settlements totaling $421 million with a trio of pharmaceutical companies that reported falsely inflated drug prices used to set government health care reimbursement rates.
On Dec. 7, the Justice Department announced that it had settled “average wholesale pricing” cases against Abbott Laboratories Inc. for $126.5 million, B. Braun Medical Inc. for $14.7 million and Roxane Laboratories Inc., which is now known as Boehringer Ingelheim Roxane Inc., for $280 million. Each company allegedly inflated the prices of numerous drugs. The government claimed the companies sold the drugs to health care providers at markedly lower prices than the published average wholesale prices paid by the Medicare and Medicaid programs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
